| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Olfaction Disorders | 36 | 2023 | 62 | 13.430 |
Why?
|
| Smell | 34 | 2023 | 109 | 6.450 |
Why?
|
| Rhinitis | 20 | 2023 | 175 | 6.020 |
Why?
|
| Sinusitis | 21 | 2023 | 210 | 5.730 |
Why?
|
| Air Pollutants | 13 | 2024 | 78 | 4.270 |
Why?
|
| Nasal Polyps | 8 | 2023 | 58 | 3.110 |
Why?
|
| Cognitive Dysfunction | 4 | 2023 | 132 | 3.000 |
Why?
|
| Air Pollution | 10 | 2024 | 68 | 2.650 |
Why?
|
| Aging | 13 | 2024 | 691 | 2.530 |
Why?
|
| Environmental Exposure | 13 | 2024 | 296 | 2.390 |
Why?
|
| Olfactory Mucosa | 10 | 2021 | 33 | 2.010 |
Why?
|
| Aged | 68 | 2024 | 18415 | 1.980 |
Why?
|
| Cognition | 8 | 2023 | 570 | 1.860 |
Why?
|
| Odorants | 9 | 2023 | 70 | 1.810 |
Why?
|
| Humans | 143 | 2024 | 86643 | 1.530 |
Why?
|
| Middle Aged | 68 | 2023 | 25028 | 1.520 |
Why?
|
| Nasal Cavity | 5 | 2013 | 91 | 1.510 |
Why?
|
| Particulate Matter | 10 | 2024 | 79 | 1.480 |
Why?
|
| Otolaryngology | 6 | 2022 | 53 | 1.390 |
Why?
|
| Alzheimer Disease | 2 | 2023 | 470 | 1.350 |
Why?
|
| Male | 98 | 2023 | 40965 | 1.330 |
Why?
|
| Aged, 80 and over | 25 | 2021 | 6509 | 1.300 |
Why?
|
| Sensation Disorders | 3 | 2017 | 23 | 1.300 |
Why?
|
| Female | 97 | 2023 | 44532 | 1.290 |
Why?
|
| Cytokines | 7 | 2020 | 776 | 1.280 |
Why?
|
| Depression | 4 | 2023 | 473 | 1.270 |
Why?
|
| United States | 28 | 2024 | 6672 | 1.240 |
Why?
|
| Paranasal Sinuses | 4 | 2019 | 60 | 1.220 |
Why?
|
| Cross-Sectional Studies | 16 | 2024 | 1621 | 1.210 |
Why?
|
| Hypersensitivity | 4 | 2023 | 154 | 1.160 |
Why?
|
| Chronic Disease | 19 | 2023 | 971 | 1.150 |
Why?
|
| Rhinitis, Allergic, Seasonal | 5 | 2016 | 179 | 1.100 |
Why?
|
| Hearing Loss | 2 | 2023 | 56 | 1.050 |
Why?
|
| Odds Ratio | 8 | 2023 | 678 | 1.010 |
Why?
|
| Sleep Apnea Syndromes | 4 | 2021 | 103 | 1.010 |
Why?
|
| Adult | 54 | 2023 | 25648 | 0.950 |
Why?
|
| Epinephrine | 4 | 2020 | 84 | 0.940 |
Why?
|
| Geriatric Assessment | 5 | 2020 | 166 | 0.910 |
Why?
|
| Nitrogen Dioxide | 3 | 2023 | 11 | 0.890 |
Why?
|
| Endoscopy | 4 | 2020 | 332 | 0.870 |
Why?
|
| Receptors, Odorant | 5 | 2016 | 37 | 0.860 |
Why?
|
| Residence Characteristics | 1 | 2024 | 197 | 0.860 |
Why?
|
| Anti-Allergic Agents | 3 | 2013 | 39 | 0.850 |
Why?
|
| Olfactory Perception | 4 | 2017 | 21 | 0.820 |
Why?
|
| Self Report | 5 | 2022 | 288 | 0.800 |
Why?
|
| Cognition Disorders | 1 | 2023 | 236 | 0.800 |
Why?
|
| Age Factors | 10 | 2021 | 1851 | 0.790 |
Why?
|
| Neurodegenerative Diseases | 2 | 2021 | 44 | 0.790 |
Why?
|
| Asthma | 5 | 2023 | 955 | 0.770 |
Why?
|
| Interleukin 1 Receptor Antagonist Protein | 1 | 2020 | 11 | 0.760 |
Why?
|
| Immunoglobulin E | 3 | 2018 | 144 | 0.750 |
Why?
|
| Interleukin-13 | 1 | 2020 | 36 | 0.740 |
Why?
|
| Olfactory Bulb | 4 | 2018 | 40 | 0.730 |
Why?
|
| Biological Products | 2 | 2020 | 143 | 0.720 |
Why?
|
| Interleukin-4 | 1 | 2020 | 127 | 0.720 |
Why?
|
| Cigarette Smoking | 1 | 2019 | 30 | 0.680 |
Why?
|
| Nasal Mucosa | 4 | 2015 | 186 | 0.680 |
Why?
|
| Motivation | 2 | 2021 | 287 | 0.670 |
Why?
|
| Cardiovascular Diseases | 4 | 2023 | 827 | 0.670 |
Why?
|
| Antibodies, Blocking | 1 | 2018 | 21 | 0.660 |
Why?
|
| Nose | 5 | 2017 | 94 | 0.660 |
Why?
|
| Comorbidity | 3 | 2017 | 943 | 0.660 |
Why?
|
| Smoking | 5 | 2023 | 609 | 0.650 |
Why?
|
| Neuropsychological Tests | 5 | 2023 | 502 | 0.650 |
Why?
|
| Exercise | 1 | 2021 | 315 | 0.640 |
Why?
|
| Biological Therapy | 1 | 2018 | 45 | 0.640 |
Why?
|
| Frontal Sinus | 1 | 2018 | 7 | 0.640 |
Why?
|
| Hospitals, Low-Volume | 1 | 2018 | 18 | 0.640 |
Why?
|
| Longitudinal Studies | 7 | 2021 | 1019 | 0.630 |
Why?
|
| Hospitals, High-Volume | 1 | 2018 | 35 | 0.620 |
Why?
|
| Geriatrics | 1 | 2018 | 61 | 0.610 |
Why?
|
| Apolipoprotein E4 | 3 | 2023 | 27 | 0.610 |
Why?
|
| Genetic Predisposition to Disease | 6 | 2021 | 2271 | 0.610 |
Why?
|
| Quality of Life | 10 | 2021 | 1585 | 0.600 |
Why?
|
| Ambulatory Surgical Procedures | 1 | 2018 | 74 | 0.600 |
Why?
|
| Eosinophilia | 1 | 2017 | 84 | 0.600 |
Why?
|
| Loneliness | 2 | 2020 | 24 | 0.590 |
Why?
|
| Immunologic Factors | 1 | 2018 | 170 | 0.590 |
Why?
|
| Independent Living | 4 | 2022 | 18 | 0.590 |
Why?
|
| Smoking Cessation | 1 | 2019 | 230 | 0.580 |
Why?
|
| Adenoidectomy | 1 | 2016 | 23 | 0.580 |
Why?
|
| Tonsillectomy | 1 | 2016 | 30 | 0.570 |
Why?
|
| Parkinson Disease | 3 | 2023 | 132 | 0.570 |
Why?
|
| Drug Utilization | 1 | 2016 | 65 | 0.560 |
Why?
|
| Antibodies, Anti-Idiotypic | 2 | 2013 | 44 | 0.560 |
Why?
|
| Pain, Postoperative | 2 | 2016 | 240 | 0.550 |
Why?
|
| Risk Factors | 13 | 2023 | 5417 | 0.550 |
Why?
|
| Olfactory Pathways | 3 | 2018 | 23 | 0.550 |
Why?
|
| Urban Population | 2 | 2016 | 213 | 0.540 |
Why?
|
| Air Pollution, Indoor | 1 | 2016 | 63 | 0.540 |
Why?
|
| Sleep Apnea, Obstructive | 5 | 2018 | 219 | 0.540 |
Why?
|
| Dementia | 1 | 2017 | 187 | 0.540 |
Why?
|
| Analgesics | 1 | 2016 | 119 | 0.540 |
Why?
|
| Sex Factors | 7 | 2020 | 1054 | 0.520 |
Why?
|
| Environmental Pollutants | 2 | 2023 | 51 | 0.510 |
Why?
|
| Imaging, Three-Dimensional | 2 | 2017 | 579 | 0.500 |
Why?
|
| Sensation | 1 | 2014 | 45 | 0.490 |
Why?
|
| Polymorphism, Single Nucleotide | 7 | 2021 | 2357 | 0.480 |
Why?
|
| Genetic Linkage | 4 | 2013 | 623 | 0.470 |
Why?
|
| Surgeons | 1 | 2018 | 238 | 0.470 |
Why?
|
| Delivery of Health Care | 1 | 2018 | 426 | 0.460 |
Why?
|
| Genome, Human | 2 | 2008 | 756 | 0.460 |
Why?
|
| T-Lymphocytes, Regulatory | 2 | 2014 | 295 | 0.460 |
Why?
|
| Surveys and Questionnaires | 8 | 2021 | 2501 | 0.440 |
Why?
|
| Microbiota | 2 | 2017 | 381 | 0.440 |
Why?
|
| Myocardial Infarction | 4 | 1999 | 376 | 0.430 |
Why?
|
| Apolipoproteins E | 2 | 2023 | 129 | 0.420 |
Why?
|
| Anti-Inflammatory Agents | 3 | 2015 | 339 | 0.410 |
Why?
|
| Genetic Loci | 1 | 2013 | 250 | 0.410 |
Why?
|
| Mental Health | 3 | 2020 | 162 | 0.400 |
Why?
|
| Tomography, X-Ray Computed | 5 | 2015 | 2601 | 0.380 |
Why?
|
| Gray Matter | 3 | 2022 | 33 | 0.380 |
Why?
|
| T-Lymphocyte Subsets | 1 | 2012 | 272 | 0.370 |
Why?
|
| Air | 4 | 2008 | 62 | 0.370 |
Why?
|
| Rhinitis, Allergic | 2 | 2023 | 43 | 0.370 |
Why?
|
| Antibodies, Monoclonal, Humanized | 2 | 2013 | 930 | 0.370 |
Why?
|
| Olfactory Receptor Neurons | 3 | 2016 | 16 | 0.360 |
Why?
|
| Logistic Models | 5 | 2023 | 1186 | 0.360 |
Why?
|
| Arrhythmias, Cardiac | 4 | 1998 | 187 | 0.350 |
Why?
|
| Adolescent | 20 | 2023 | 8981 | 0.350 |
Why?
|
| Gene Expression Regulation | 5 | 2016 | 1920 | 0.350 |
Why?
|
| Hearing | 2 | 2023 | 59 | 0.340 |
Why?
|
| Genome-Wide Association Study | 5 | 2021 | 1621 | 0.340 |
Why?
|
| Rhinovirus | 3 | 2023 | 25 | 0.330 |
Why?
|
| Sexual Behavior | 3 | 2023 | 302 | 0.330 |
Why?
|
| Respiratory Tract Infections | 2 | 2020 | 105 | 0.330 |
Why?
|
| Dogs | 9 | 2016 | 685 | 0.330 |
Why?
|
| Chromosomes, Human, Pair 7 | 1 | 2008 | 79 | 0.330 |
Why?
|
| Urban Health | 1 | 2008 | 55 | 0.320 |
Why?
|
| Cardiac Complexes, Premature | 4 | 1992 | 7 | 0.320 |
Why?
|
| Chromosomes, Human, Pair 4 | 1 | 2008 | 48 | 0.320 |
Why?
|
| Adrenal Cortex Hormones | 3 | 2021 | 263 | 0.310 |
Why?
|
| Administration, Intranasal | 5 | 2011 | 136 | 0.310 |
Why?
|
| Medicare | 2 | 2023 | 410 | 0.300 |
Why?
|
| Orbital Fractures | 1 | 2007 | 13 | 0.300 |
Why?
|
| Maxillary Sinusitis | 1 | 2007 | 16 | 0.300 |
Why?
|
| Water | 2 | 2007 | 277 | 0.300 |
Why?
|
| Olfactory Cortex | 2 | 2018 | 5 | 0.300 |
Why?
|
| Young Adult | 15 | 2023 | 5976 | 0.290 |
Why?
|
| Saline Solution, Hypertonic | 1 | 2006 | 24 | 0.280 |
Why?
|
| Tracheotomy | 2 | 2007 | 18 | 0.280 |
Why?
|
| Sodium Chloride | 1 | 2006 | 88 | 0.270 |
Why?
|
| Vitamin D | 1 | 2008 | 261 | 0.270 |
Why?
|
| Prognosis | 6 | 2020 | 3679 | 0.270 |
Why?
|
| Purkinje Cells | 2 | 1998 | 80 | 0.270 |
Why?
|
| Phenoxybenzamine | 1 | 2005 | 15 | 0.260 |
Why?
|
| Adrenergic alpha-Antagonists | 1 | 2005 | 35 | 0.260 |
Why?
|
| Body Temperature | 1 | 2005 | 124 | 0.250 |
Why?
|
| Genetic Testing | 1 | 2008 | 535 | 0.250 |
Why?
|
| Inhalation | 3 | 2010 | 31 | 0.250 |
Why?
|
| Postoperative Complications | 2 | 2007 | 2207 | 0.240 |
Why?
|
| Humidity | 5 | 2008 | 89 | 0.240 |
Why?
|
| Pharyngeal Neoplasms | 1 | 2024 | 15 | 0.240 |
Why?
|
| Budesonide | 1 | 2004 | 45 | 0.240 |
Why?
|
| Antibodies, Monoclonal | 1 | 2010 | 1376 | 0.240 |
Why?
|
| Allergens | 3 | 2016 | 179 | 0.240 |
Why?
|
| Prospective Studies | 8 | 2023 | 4213 | 0.240 |
Why?
|
| Inflammation | 4 | 2019 | 920 | 0.240 |
Why?
|
| Ibuprofen | 1 | 2023 | 28 | 0.230 |
Why?
|
| Incidence | 3 | 2024 | 1577 | 0.230 |
Why?
|
| Risk | 3 | 2020 | 674 | 0.230 |
Why?
|
| Eustachian Tube | 1 | 2023 | 9 | 0.230 |
Why?
|
| Ear Diseases | 1 | 2023 | 19 | 0.220 |
Why?
|
| Neurogenic Inflammation | 1 | 2002 | 2 | 0.220 |
Why?
|
| DNA | 1 | 2008 | 1294 | 0.220 |
Why?
|
| Animals | 26 | 2022 | 26582 | 0.220 |
Why?
|
| Social Isolation | 1 | 2023 | 67 | 0.220 |
Why?
|
| Vision Disorders | 1 | 2023 | 75 | 0.220 |
Why?
|
| Insurance Coverage | 1 | 2023 | 117 | 0.220 |
Why?
|
| Education, Medical, Graduate | 3 | 2016 | 369 | 0.210 |
Why?
|
| Frailty | 1 | 2023 | 58 | 0.210 |
Why?
|
| Genotype | 3 | 2023 | 1851 | 0.210 |
Why?
|
| Epigenesis, Genetic | 2 | 2023 | 479 | 0.210 |
Why?
|
| Executive Function | 1 | 2023 | 86 | 0.210 |
Why?
|
| NF-E2-Related Factor 2 | 1 | 2022 | 41 | 0.210 |
Why?
|
| Insurance | 1 | 2022 | 11 | 0.210 |
Why?
|
| Rhinitis, Allergic, Perennial | 1 | 2002 | 81 | 0.210 |
Why?
|
| Coronary Disease | 3 | 1992 | 261 | 0.210 |
Why?
|
| Epithelial Cells | 2 | 2023 | 669 | 0.210 |
Why?
|
| Double-Blind Method | 5 | 2016 | 1823 | 0.200 |
Why?
|
| Patient Satisfaction | 2 | 2022 | 455 | 0.200 |
Why?
|
| Ambulatory Care Facilities | 1 | 2022 | 102 | 0.200 |
Why?
|
| Respiratory Tract Diseases | 1 | 2001 | 45 | 0.200 |
Why?
|
| Continuous Positive Airway Pressure | 2 | 2014 | 53 | 0.200 |
Why?
|
| Accelerometry | 1 | 2021 | 36 | 0.200 |
Why?
|
| Thrombophlebitis | 1 | 2001 | 25 | 0.200 |
Why?
|
| Medication Therapy Management | 1 | 2021 | 16 | 0.200 |
Why?
|
| Patient Selection | 2 | 2018 | 685 | 0.200 |
Why?
|
| Arousal | 5 | 1995 | 170 | 0.200 |
Why?
|
| Taste Disorders | 1 | 2020 | 7 | 0.190 |
Why?
|
| Pregnadienediols | 2 | 2011 | 13 | 0.190 |
Why?
|
| Prevalence | 4 | 2023 | 1239 | 0.190 |
Why?
|
| Cystic Fibrosis Transmembrane Conductance Regulator | 2 | 2013 | 57 | 0.190 |
Why?
|
| Immunity, Mucosal | 2 | 2021 | 69 | 0.190 |
Why?
|
| Population Surveillance | 2 | 2014 | 219 | 0.190 |
Why?
|
| Cohort Studies | 3 | 2023 | 2767 | 0.190 |
Why?
|
| Personal Satisfaction | 1 | 2021 | 62 | 0.190 |
Why?
|
| Body Composition | 1 | 2020 | 68 | 0.190 |
Why?
|
| Cross-Over Studies | 5 | 2016 | 399 | 0.190 |
Why?
|
| Angiography | 1 | 2001 | 208 | 0.190 |
Why?
|
| Hemostasis | 1 | 2020 | 21 | 0.180 |
Why?
|
| Tyrosine | 2 | 1991 | 133 | 0.180 |
Why?
|
| Viruses | 1 | 2020 | 78 | 0.180 |
Why?
|
| Combined Modality Therapy | 4 | 2018 | 1686 | 0.180 |
Why?
|
| Retrospective Studies | 9 | 2021 | 8489 | 0.180 |
Why?
|
| Neurologic Examination | 1 | 2020 | 118 | 0.180 |
Why?
|
| Organ Specificity | 1 | 2020 | 258 | 0.180 |
Why?
|
| Disease Models, Animal | 6 | 2022 | 2232 | 0.180 |
Why?
|
| Radiography, Thoracic | 1 | 2001 | 320 | 0.180 |
Why?
|
| Pneumonia | 1 | 2021 | 179 | 0.180 |
Why?
|
| Hearing Loss, Sensorineural | 2 | 2011 | 46 | 0.180 |
Why?
|
| Disabled Persons | 1 | 2020 | 67 | 0.170 |
Why?
|
| Social Networking | 1 | 2020 | 75 | 0.170 |
Why?
|
| Nanostructures | 1 | 2020 | 77 | 0.170 |
Why?
|
| Communication | 1 | 2023 | 441 | 0.170 |
Why?
|
| Biological Transport, Active | 1 | 1999 | 102 | 0.170 |
Why?
|
| C-Reactive Protein | 1 | 2020 | 190 | 0.170 |
Why?
|
| Biomarkers | 3 | 2023 | 1718 | 0.170 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 2 | 2023 | 243 | 0.170 |
Why?
|
| Emotions | 1 | 2023 | 341 | 0.170 |
Why?
|
| Weight Loss | 1 | 2020 | 229 | 0.170 |
Why?
|
| Follow-Up Studies | 5 | 2020 | 3640 | 0.170 |
Why?
|
| Telemedicine | 1 | 2021 | 169 | 0.170 |
Why?
|
| Treatment Outcome | 5 | 2019 | 7993 | 0.170 |
Why?
|
| Socioeconomic Factors | 1 | 2021 | 567 | 0.160 |
Why?
|
| Demography | 2 | 2016 | 177 | 0.160 |
Why?
|
| Ethmoid Sinus | 1 | 2018 | 6 | 0.160 |
Why?
|
| New Jersey | 1 | 2018 | 4 | 0.160 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2020 | 879 | 0.160 |
Why?
|
| Kentucky | 1 | 2018 | 14 | 0.160 |
Why?
|
| Blood Pressure | 8 | 2018 | 1143 | 0.160 |
Why?
|
| Pulmonary Embolism | 1 | 2001 | 222 | 0.160 |
Why?
|
| Apnea | 1 | 2018 | 29 | 0.160 |
Why?
|
| Florida | 1 | 2018 | 55 | 0.160 |
Why?
|
| Chromosome Mapping | 3 | 2017 | 1074 | 0.160 |
Why?
|
| Polysomnography | 5 | 2018 | 151 | 0.160 |
Why?
|
| Paranasal Sinus Diseases | 1 | 2018 | 25 | 0.160 |
Why?
|
| Myocardial Ischemia | 1 | 1999 | 162 | 0.160 |
Why?
|
| Magnetic Resonance Imaging | 5 | 2022 | 3362 | 0.160 |
Why?
|
| Anti-Arrhythmia Agents | 1 | 1998 | 58 | 0.160 |
Why?
|
| Nose Neoplasms | 1 | 2017 | 31 | 0.150 |
Why?
|
| Neck | 1 | 2018 | 100 | 0.150 |
Why?
|
| Ion Channels | 1 | 1999 | 246 | 0.150 |
Why?
|
| Head | 1 | 2018 | 132 | 0.150 |
Why?
|
| Sexual Dysfunction, Physiological | 1 | 2018 | 67 | 0.150 |
Why?
|
| Head and Neck Neoplasms | 2 | 2024 | 1052 | 0.150 |
Why?
|
| Epigenomics | 1 | 2018 | 100 | 0.150 |
Why?
|
| Morbidity | 1 | 2017 | 148 | 0.150 |
Why?
|
| Actinobacteria | 1 | 2017 | 11 | 0.150 |
Why?
|
| Codeine | 1 | 2016 | 12 | 0.150 |
Why?
|
| Reproducibility of Results | 3 | 2022 | 2705 | 0.150 |
Why?
|
| Renal Insufficiency, Chronic | 1 | 2022 | 350 | 0.150 |
Why?
|
| Hypertension, Renal | 3 | 1993 | 40 | 0.150 |
Why?
|
| Heart Rate | 7 | 1995 | 492 | 0.150 |
Why?
|
| Nasopharynx | 1 | 2017 | 47 | 0.150 |
Why?
|
| Databases, Factual | 2 | 2018 | 814 | 0.150 |
Why?
|
| Nasal Surgical Procedures | 1 | 2016 | 8 | 0.150 |
Why?
|
| Spatio-Temporal Analysis | 1 | 2016 | 21 | 0.150 |
Why?
|
| Geographic Information Systems | 1 | 2016 | 20 | 0.150 |
Why?
|
| Sendai virus | 1 | 2016 | 8 | 0.150 |
Why?
|
| Respirovirus Infections | 1 | 2016 | 12 | 0.140 |
Why?
|
| Educational Status | 2 | 2017 | 188 | 0.140 |
Why?
|
| Case-Control Studies | 4 | 2022 | 1805 | 0.140 |
Why?
|
| Clinical Trials as Topic | 2 | 2020 | 1169 | 0.140 |
Why?
|
| Lipocalins | 1 | 2016 | 35 | 0.140 |
Why?
|
| Sleep | 2 | 2018 | 444 | 0.140 |
Why?
|
| Piperidines | 1 | 1998 | 181 | 0.140 |
Why?
|
| Radiotherapy, Adjuvant | 1 | 2017 | 292 | 0.140 |
Why?
|
| Pedigree | 2 | 2008 | 966 | 0.140 |
Why?
|
| Eosinophils | 2 | 2010 | 194 | 0.140 |
Why?
|
| Professionalism | 1 | 2016 | 24 | 0.140 |
Why?
|
| Research Design | 2 | 2021 | 594 | 0.140 |
Why?
|
| Cellulose | 1 | 2016 | 55 | 0.140 |
Why?
|
| Cost-Benefit Analysis | 1 | 2018 | 454 | 0.140 |
Why?
|
| Temperature | 3 | 2023 | 396 | 0.140 |
Why?
|
| Pyridines | 1 | 1998 | 310 | 0.140 |
Why?
|
| Hemodynamics | 3 | 1995 | 710 | 0.140 |
Why?
|
| Plant Extracts | 1 | 2018 | 244 | 0.140 |
Why?
|
| Cell Separation | 2 | 2014 | 196 | 0.140 |
Why?
|
| Potassium Channels | 1 | 1998 | 340 | 0.130 |
Why?
|
| Glucocorticoids | 1 | 2018 | 352 | 0.130 |
Why?
|
| Action Potentials | 1 | 1999 | 573 | 0.130 |
Why?
|
| Blood Coagulation | 1 | 2015 | 91 | 0.130 |
Why?
|
| Papilloma, Inverted | 1 | 2015 | 6 | 0.130 |
Why?
|
| Nerve Growth Factors | 1 | 2015 | 63 | 0.130 |
Why?
|
| Intermediate Filament Proteins | 1 | 2015 | 35 | 0.130 |
Why?
|
| Disease Progression | 1 | 2020 | 1531 | 0.130 |
Why?
|
| Paranasal Sinus Neoplasms | 1 | 2015 | 24 | 0.130 |
Why?
|
| Housing | 1 | 2015 | 42 | 0.130 |
Why?
|
| Hypersensitivity, Immediate | 1 | 2015 | 62 | 0.130 |
Why?
|
| Simulation Training | 1 | 2016 | 88 | 0.130 |
Why?
|
| Linear Models | 1 | 2016 | 421 | 0.130 |
Why?
|
| Pregnancy | 1 | 2022 | 2894 | 0.120 |
Why?
|
| Transcriptome | 2 | 2016 | 580 | 0.120 |
Why?
|
| Vision, Ocular | 1 | 2014 | 71 | 0.120 |
Why?
|
| Atherosclerosis | 1 | 2017 | 244 | 0.120 |
Why?
|
| Flow Cytometry | 2 | 2014 | 679 | 0.120 |
Why?
|
| Olfactory Nerve | 1 | 2013 | 2 | 0.120 |
Why?
|
| Child | 6 | 2023 | 6927 | 0.120 |
Why?
|
| Respiratory System | 1 | 2014 | 116 | 0.120 |
Why?
|
| Internship and Residency | 3 | 2014 | 1004 | 0.120 |
Why?
|
| Trigeminal Nerve | 1 | 2013 | 18 | 0.120 |
Why?
|
| Poaceae | 2 | 2011 | 19 | 0.120 |
Why?
|
| Mometasone Furoate | 2 | 2011 | 18 | 0.120 |
Why?
|
| Genome | 2 | 2018 | 372 | 0.120 |
Why?
|
| Personnel Selection | 1 | 2014 | 59 | 0.120 |
Why?
|
| Signal Transduction | 3 | 2016 | 3241 | 0.120 |
Why?
|
| Macaca mulatta | 1 | 2016 | 459 | 0.120 |
Why?
|
| Nasal Obstruction | 2 | 2020 | 21 | 0.120 |
Why?
|
| Dexamethasone | 1 | 2015 | 326 | 0.120 |
Why?
|
| Touch | 1 | 2014 | 89 | 0.120 |
Why?
|
| Prednisone | 1 | 2014 | 258 | 0.120 |
Why?
|
| Pulmonary Disease, Chronic Obstructive | 1 | 2016 | 247 | 0.110 |
Why?
|
| Arachidonic Acid | 1 | 2013 | 63 | 0.110 |
Why?
|
| Lipids | 1 | 2014 | 269 | 0.110 |
Why?
|
| Pollen | 2 | 2011 | 80 | 0.110 |
Why?
|
| Melanoma | 1 | 2017 | 459 | 0.110 |
Why?
|
| Mice | 7 | 2022 | 11352 | 0.110 |
Why?
|
| Calcium Channels | 1 | 1994 | 182 | 0.110 |
Why?
|
| Myocardial Reperfusion | 1 | 1992 | 27 | 0.110 |
Why?
|
| Blood Circulation | 1 | 2012 | 29 | 0.110 |
Why?
|
| Cells, Cultured | 3 | 2016 | 2818 | 0.110 |
Why?
|
| Social Class | 1 | 2013 | 128 | 0.110 |
Why?
|
| Social Behavior | 2 | 2014 | 294 | 0.110 |
Why?
|
| Diagnosis, Differential | 3 | 2008 | 1565 | 0.110 |
Why?
|
| Analgesics, Opioid | 1 | 2016 | 413 | 0.110 |
Why?
|
| Brain | 1 | 2022 | 2216 | 0.100 |
Why?
|
| Antigens | 1 | 2013 | 228 | 0.100 |
Why?
|
| Adaptive Immunity | 1 | 2013 | 164 | 0.100 |
Why?
|
| Skull Base | 2 | 2022 | 47 | 0.100 |
Why?
|
| Severity of Illness Index | 1 | 2017 | 1801 | 0.100 |
Why?
|
| Health Behavior | 1 | 2013 | 183 | 0.100 |
Why?
|
| Antigen Presentation | 1 | 2013 | 209 | 0.100 |
Why?
|
| Hearing Loss, Bilateral | 1 | 2011 | 9 | 0.100 |
Why?
|
| Hearing Aids | 1 | 2011 | 8 | 0.100 |
Why?
|
| Databases, Genetic | 1 | 2012 | 260 | 0.100 |
Why?
|
| Airway Management | 1 | 2012 | 46 | 0.100 |
Why?
|
| Diazepam | 1 | 1991 | 28 | 0.100 |
Why?
|
| Anxiety | 1 | 2013 | 287 | 0.100 |
Why?
|
| Coronary Vessels | 1 | 1992 | 177 | 0.100 |
Why?
|
| Chemoreceptor Cells | 1 | 2011 | 65 | 0.100 |
Why?
|
| Blepharoptosis | 1 | 2010 | 11 | 0.100 |
Why?
|
| Omalizumab | 1 | 2010 | 8 | 0.100 |
Why?
|
| Mutation | 2 | 2015 | 3968 | 0.100 |
Why?
|
| Health Status | 1 | 2013 | 360 | 0.100 |
Why?
|
| Blepharoplasty | 1 | 2010 | 8 | 0.100 |
Why?
|
| Agnosia | 1 | 2010 | 5 | 0.100 |
Why?
|
| Eyelids | 1 | 2010 | 23 | 0.100 |
Why?
|
| Speech Perception | 1 | 2011 | 71 | 0.100 |
Why?
|
| Conjunctiva | 1 | 2010 | 19 | 0.100 |
Why?
|
| Ambrosia | 1 | 2010 | 14 | 0.100 |
Why?
|
| Oculomotor Muscles | 1 | 2010 | 28 | 0.100 |
Why?
|
| Antigens, CD | 1 | 2012 | 458 | 0.090 |
Why?
|
| Bacteria | 1 | 2014 | 447 | 0.090 |
Why?
|
| RNA, Messenger | 1 | 2016 | 1981 | 0.090 |
Why?
|
| Alcohol Drinking | 1 | 2013 | 267 | 0.090 |
Why?
|
| Health Status Indicators | 1 | 2010 | 105 | 0.090 |
Why?
|
| Swine | 6 | 1995 | 555 | 0.090 |
Why?
|
| Genetic Variation | 2 | 2017 | 1351 | 0.090 |
Why?
|
| Electrocardiography | 2 | 1995 | 478 | 0.090 |
Why?
|
| Anesthesiology | 1 | 2012 | 157 | 0.090 |
Why?
|
| Pennsylvania | 2 | 2019 | 75 | 0.090 |
Why?
|
| Immunity, Innate | 1 | 2013 | 409 | 0.090 |
Why?
|
| Infant | 4 | 2023 | 3046 | 0.090 |
Why?
|
| Multigene Family | 1 | 2010 | 202 | 0.090 |
Why?
|
| Muscle, Smooth | 1 | 2010 | 354 | 0.080 |
Why?
|
| Clonidine | 1 | 1989 | 37 | 0.080 |
Why?
|
| Job Application | 1 | 2008 | 8 | 0.080 |
Why?
|
| Naloxone | 1 | 1989 | 59 | 0.080 |
Why?
|
| Recovery of Function | 1 | 2010 | 272 | 0.080 |
Why?
|
| Chicago | 2 | 2023 | 1379 | 0.080 |
Why?
|
| Hospitalization | 2 | 2021 | 849 | 0.080 |
Why?
|
| HLA Antigens | 1 | 2010 | 232 | 0.080 |
Why?
|
| Vestibular Diseases | 1 | 2008 | 27 | 0.080 |
Why?
|
| Vestibular Nerve | 1 | 2008 | 33 | 0.080 |
Why?
|
| South Dakota | 1 | 2008 | 47 | 0.080 |
Why?
|
| Nasal Provocation Tests | 1 | 2008 | 129 | 0.080 |
Why?
|
| Hot Temperature | 1 | 2008 | 206 | 0.080 |
Why?
|
| Temporal Bone | 1 | 2008 | 66 | 0.080 |
Why?
|
| Nasal Bone | 1 | 2007 | 5 | 0.080 |
Why?
|
| Eye | 1 | 2008 | 111 | 0.080 |
Why?
|
| Skull Fractures | 1 | 2007 | 24 | 0.080 |
Why?
|
| Mobile Health Units | 1 | 2007 | 11 | 0.070 |
Why?
|
| Sensory Thresholds | 2 | 2018 | 54 | 0.070 |
Why?
|
| Orbital Diseases | 1 | 2007 | 21 | 0.070 |
Why?
|
| Algorithms | 1 | 2015 | 1830 | 0.070 |
Why?
|
| Sheep | 1 | 2007 | 239 | 0.070 |
Why?
|
| Abscess | 1 | 2007 | 91 | 0.070 |
Why?
|
| Clinical Competence | 1 | 2012 | 751 | 0.070 |
Why?
|
| Evoked Potentials | 2 | 2018 | 190 | 0.070 |
Why?
|
| Cause of Death | 2 | 2019 | 277 | 0.070 |
Why?
|
| Organ Size | 2 | 2018 | 364 | 0.070 |
Why?
|
| Rabbits | 1 | 2007 | 636 | 0.070 |
Why?
|
| Equipment Design | 1 | 2007 | 406 | 0.070 |
Why?
|
| Headache | 1 | 2006 | 73 | 0.070 |
Why?
|
| Time Factors | 5 | 2011 | 5210 | 0.070 |
Why?
|
| Respiratory Hypersensitivity | 1 | 2005 | 41 | 0.070 |
Why?
|
| Quantitative Trait Loci | 2 | 2021 | 576 | 0.070 |
Why?
|
| Antigens, Differentiation, T-Lymphocyte | 1 | 2005 | 95 | 0.070 |
Why?
|
| Placebo Effect | 1 | 2005 | 31 | 0.070 |
Why?
|
| Cardiomegaly | 2 | 1999 | 111 | 0.060 |
Why?
|
| China | 2 | 2016 | 228 | 0.060 |
Why?
|
| Polymorphism, Genetic | 1 | 2008 | 819 | 0.060 |
Why?
|
| In Vitro Techniques | 2 | 1998 | 989 | 0.060 |
Why?
|
| Coronary Circulation | 3 | 1995 | 130 | 0.060 |
Why?
|
| Th2 Cells | 1 | 2005 | 146 | 0.060 |
Why?
|
| Pain Measurement | 1 | 2006 | 321 | 0.060 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2007 | 689 | 0.060 |
Why?
|
| Gene Expression | 2 | 2021 | 1284 | 0.060 |
Why?
|
| Resistin | 1 | 2023 | 14 | 0.060 |
Why?
|
| Ghrelin | 1 | 2023 | 29 | 0.060 |
Why?
|
| Analysis of Variance | 1 | 2006 | 912 | 0.060 |
Why?
|
| Histamine Antagonists | 1 | 2023 | 12 | 0.060 |
Why?
|
| Nasal Decongestants | 1 | 2023 | 10 | 0.060 |
Why?
|
| Interleukin-3 | 1 | 2023 | 36 | 0.060 |
Why?
|
| Troponin | 1 | 2023 | 24 | 0.060 |
Why?
|
| Medically Uninsured | 1 | 2023 | 58 | 0.060 |
Why?
|
| C-Peptide | 1 | 2023 | 174 | 0.060 |
Why?
|
| Gene Expression Profiling | 3 | 2016 | 1384 | 0.060 |
Why?
|
| Hallucinations | 1 | 2023 | 27 | 0.060 |
Why?
|
| Leptin | 1 | 2023 | 105 | 0.060 |
Why?
|
| Brazil | 1 | 2023 | 69 | 0.060 |
Why?
|
| Interleukin-12 | 1 | 2023 | 108 | 0.060 |
Why?
|
| Norepinephrine | 2 | 1993 | 167 | 0.050 |
Why?
|
| Pseudogenes | 2 | 2016 | 35 | 0.050 |
Why?
|
| Insurance, Health | 1 | 2023 | 160 | 0.050 |
Why?
|
| Nutrition Surveys | 1 | 2023 | 114 | 0.050 |
Why?
|
| Interleukin-6 | 1 | 2023 | 256 | 0.050 |
Why?
|
| Aspirin | 1 | 2023 | 156 | 0.050 |
Why?
|
| Anger | 1 | 2023 | 78 | 0.050 |
Why?
|
| Ambulatory Care | 1 | 2023 | 181 | 0.050 |
Why?
|
| Promoter Regions, Genetic | 1 | 2005 | 937 | 0.050 |
Why?
|
| Genes, erbB-2 | 1 | 2021 | 24 | 0.050 |
Why?
|
| Maryland | 1 | 2021 | 35 | 0.050 |
Why?
|
| Baltimore | 1 | 2021 | 36 | 0.050 |
Why?
|
| Office Visits | 1 | 2021 | 44 | 0.050 |
Why?
|
| Sympathetic Nervous System | 2 | 1992 | 104 | 0.050 |
Why?
|
| Remission, Spontaneous | 1 | 2021 | 53 | 0.050 |
Why?
|
| Cost of Illness | 1 | 2022 | 150 | 0.050 |
Why?
|
| Epithelium | 1 | 2022 | 319 | 0.050 |
Why?
|
| High-Throughput Nucleotide Sequencing | 2 | 2016 | 456 | 0.050 |
Why?
|
| Sex Characteristics | 2 | 2016 | 319 | 0.050 |
Why?
|
| Anisakiasis | 1 | 2000 | 1 | 0.050 |
Why?
|
| Medicaid | 1 | 2023 | 217 | 0.050 |
Why?
|
| Coronavirus OC43, Human | 1 | 2020 | 7 | 0.050 |
Why?
|
| Catecholamines | 2 | 1991 | 88 | 0.050 |
Why?
|
| Mesentery | 1 | 2000 | 45 | 0.050 |
Why?
|
| Regenerative Medicine | 1 | 2020 | 23 | 0.050 |
Why?
|
| National Institute of Allergy and Infectious Diseases (U.S.) | 1 | 2020 | 4 | 0.050 |
Why?
|
| Consensus | 1 | 2022 | 335 | 0.050 |
Why?
|
| Glomerular Filtration Rate | 1 | 2022 | 384 | 0.050 |
Why?
|
| Absorptiometry, Photon | 1 | 2020 | 99 | 0.050 |
Why?
|
| Small Molecule Libraries | 1 | 2020 | 61 | 0.050 |
Why?
|
| Microscopy, Electron, Transmission | 1 | 2020 | 134 | 0.050 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2023 | 683 | 0.050 |
Why?
|
| Physical Stimulation | 3 | 2015 | 70 | 0.050 |
Why?
|
| Observational Studies as Topic | 1 | 2020 | 48 | 0.050 |
Why?
|
| Bayes Theorem | 1 | 2021 | 361 | 0.050 |
Why?
|
| Needs Assessment | 1 | 2021 | 154 | 0.050 |
Why?
|
| Congresses as Topic | 1 | 2020 | 116 | 0.050 |
Why?
|
| Global Health | 1 | 2021 | 193 | 0.040 |
Why?
|
| Tennessee | 1 | 2019 | 17 | 0.040 |
Why?
|
| Sarcolemma | 1 | 1999 | 30 | 0.040 |
Why?
|
| Neurosurgical Procedures | 1 | 2021 | 213 | 0.040 |
Why?
|
| Stem Cell Transplantation | 1 | 2020 | 183 | 0.040 |
Why?
|
| Guinea Pigs | 1 | 1999 | 171 | 0.040 |
Why?
|
| Ion Transport | 1 | 1999 | 81 | 0.040 |
Why?
|
| Mice, Inbred C57BL | 2 | 2016 | 3092 | 0.040 |
Why?
|
| Behavior, Animal | 2 | 1992 | 373 | 0.040 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 1 | 2021 | 199 | 0.040 |
Why?
|
| Psychophysics | 1 | 2018 | 80 | 0.040 |
Why?
|
| Genetic Therapy | 1 | 2020 | 342 | 0.040 |
Why?
|
| National Institute of Environmental Health Sciences (U.S.) | 1 | 2018 | 3 | 0.040 |
Why?
|
| Cesium | 1 | 1998 | 25 | 0.040 |
Why?
|
| Ginkgo biloba | 1 | 2018 | 5 | 0.040 |
Why?
|
| 4-Aminopyridine | 1 | 1998 | 32 | 0.040 |
Why?
|
| Sleep Stages | 1 | 2018 | 45 | 0.040 |
Why?
|
| Respiratory Rate | 1 | 2018 | 20 | 0.040 |
Why?
|
| Stem Cells | 1 | 2020 | 351 | 0.040 |
Why?
|
| Child, Preschool | 3 | 2001 | 3612 | 0.040 |
Why?
|
| Lymphography | 1 | 1977 | 27 | 0.040 |
Why?
|
| Margins of Excision | 1 | 2017 | 39 | 0.040 |
Why?
|
| Oximetry | 1 | 2018 | 84 | 0.040 |
Why?
|
| Sleep, REM | 2 | 1995 | 50 | 0.040 |
Why?
|
| Olfactometry | 1 | 2017 | 1 | 0.040 |
Why?
|
| Actigraphy | 1 | 2017 | 51 | 0.040 |
Why?
|
| Activities of Daily Living | 1 | 2018 | 204 | 0.040 |
Why?
|
| Calcium Channel Blockers | 1 | 1998 | 203 | 0.040 |
Why?
|
| DNA Methylation | 1 | 2021 | 628 | 0.040 |
Why?
|
| Patch-Clamp Techniques | 1 | 1998 | 396 | 0.040 |
Why?
|
| Nasal Sprays | 1 | 2016 | 9 | 0.040 |
Why?
|
| Fatty Acid-Binding Proteins | 1 | 2016 | 26 | 0.040 |
Why?
|
| Membrane Potentials | 1 | 1998 | 435 | 0.040 |
Why?
|
| Myocardium | 1 | 1999 | 529 | 0.040 |
Why?
|
| Data Interpretation, Statistical | 1 | 1998 | 297 | 0.030 |
Why?
|
| Neuropeptides | 1 | 2016 | 112 | 0.030 |
Why?
|
| RNA, Ribosomal, 16S | 1 | 2017 | 241 | 0.030 |
Why?
|
| T-Lymphocytes | 1 | 2002 | 1195 | 0.030 |
Why?
|
| Lymphoma | 1 | 1977 | 262 | 0.030 |
Why?
|
| Autoantigens | 1 | 2016 | 127 | 0.030 |
Why?
|
| Infant, Newborn | 1 | 2001 | 2379 | 0.030 |
Why?
|
| Protein Isoforms | 1 | 2016 | 270 | 0.030 |
Why?
|
| Mice, Inbred BALB C | 1 | 2018 | 1047 | 0.030 |
Why?
|
| Neoplasm Staging | 2 | 2017 | 1939 | 0.030 |
Why?
|
| Health Status Disparities | 1 | 2017 | 170 | 0.030 |
Why?
|
| Membrane Transport Proteins | 1 | 2016 | 166 | 0.030 |
Why?
|
| Snoring | 1 | 2014 | 12 | 0.030 |
Why?
|
| 1-Butanol | 1 | 2014 | 3 | 0.030 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2017 | 860 | 0.030 |
Why?
|
| Natural Orifice Endoscopic Surgery | 1 | 2015 | 38 | 0.030 |
Why?
|
| Rhinometry, Acoustic | 1 | 2014 | 3 | 0.030 |
Why?
|
| Adrenergic beta-Antagonists | 1 | 1995 | 152 | 0.030 |
Why?
|
| Electrophysiology | 2 | 1992 | 401 | 0.030 |
Why?
|
| Androstadienes | 1 | 2014 | 72 | 0.030 |
Why?
|
| Transcription, Genetic | 1 | 1999 | 1135 | 0.030 |
Why?
|
| GATA3 Transcription Factor | 1 | 2014 | 48 | 0.030 |
Why?
|
| Models, Animal | 1 | 2015 | 263 | 0.030 |
Why?
|
| Phentolamine | 1 | 1993 | 7 | 0.030 |
Why?
|
| Ventricular Fibrillation | 2 | 1992 | 65 | 0.030 |
Why?
|
| Reaction Time | 1 | 2015 | 309 | 0.030 |
Why?
|
| Cardiac Pacing, Artificial | 2 | 1991 | 87 | 0.030 |
Why?
|
| Vascular Resistance | 1 | 1993 | 102 | 0.030 |
Why?
|
| Electrodes | 1 | 1993 | 78 | 0.030 |
Why?
|
| Medical History Taking | 1 | 2013 | 80 | 0.030 |
Why?
|
| Survival Rate | 1 | 2017 | 1863 | 0.030 |
Why?
|
| Carrier Proteins | 1 | 2017 | 673 | 0.030 |
Why?
|
| Forkhead Transcription Factors | 1 | 2014 | 166 | 0.030 |
Why?
|
| Oxygen | 1 | 2018 | 726 | 0.030 |
Why?
|
| Drug Resistance | 1 | 2013 | 256 | 0.030 |
Why?
|
| INDEL Mutation | 1 | 2012 | 30 | 0.030 |
Why?
|
| Constriction | 1 | 1992 | 27 | 0.030 |
Why?
|
| Hypoxia | 1 | 2018 | 641 | 0.030 |
Why?
|
| Rats | 1 | 1999 | 3990 | 0.030 |
Why?
|
| Airway Obstruction | 1 | 1993 | 109 | 0.030 |
Why?
|
| Trachea | 1 | 1993 | 293 | 0.030 |
Why?
|
| Image Processing, Computer-Assisted | 1 | 2018 | 1204 | 0.030 |
Why?
|
| Proportional Hazards Models | 1 | 2014 | 859 | 0.030 |
Why?
|
| Tachycardia | 1 | 1991 | 35 | 0.030 |
Why?
|
| Cell Survival | 1 | 1994 | 969 | 0.030 |
Why?
|
| Proteome | 1 | 2012 | 124 | 0.030 |
Why?
|
| DNA Copy Number Variations | 1 | 2012 | 171 | 0.030 |
Why?
|
| Audiometry, Pure-Tone | 1 | 2011 | 25 | 0.020 |
Why?
|
| Evidence-Based Medicine | 1 | 2013 | 429 | 0.020 |
Why?
|
| Creatine Kinase | 1 | 1991 | 52 | 0.020 |
Why?
|
| Phylogeny | 1 | 2016 | 1137 | 0.020 |
Why?
|
| Premedication | 1 | 1991 | 54 | 0.020 |
Why?
|
| Survival Analysis | 1 | 2014 | 1538 | 0.020 |
Why?
|
| Proteins | 1 | 2016 | 777 | 0.020 |
Why?
|
| Lidocaine | 1 | 1991 | 63 | 0.020 |
Why?
|
| Species Specificity | 1 | 2012 | 678 | 0.020 |
Why?
|
| Elastic Tissue | 1 | 2010 | 18 | 0.020 |
Why?
|
| Trees | 1 | 2011 | 30 | 0.020 |
Why?
|
| Valine | 1 | 1991 | 69 | 0.020 |
Why?
|
| Software | 1 | 2015 | 654 | 0.020 |
Why?
|
| Body Mass Index | 1 | 2014 | 770 | 0.020 |
Why?
|
| Tendons | 1 | 2010 | 44 | 0.020 |
Why?
|
| Cell Proliferation | 1 | 2016 | 1578 | 0.020 |
Why?
|
| Random Allocation | 1 | 1991 | 332 | 0.020 |
Why?
|
| Internet | 1 | 2012 | 312 | 0.020 |
Why?
|
| Pheromones, Human | 1 | 2010 | 7 | 0.020 |
Why?
|
| Apoptosis | 1 | 2016 | 1683 | 0.020 |
Why?
|
| Chromosomes, Human, Pair 6 | 1 | 2010 | 125 | 0.020 |
Why?
|
| Heart | 1 | 1992 | 539 | 0.020 |
Why?
|
| Drug Interactions | 1 | 1990 | 248 | 0.020 |
Why?
|
| Hypertension | 1 | 2018 | 1141 | 0.020 |
Why?
|
| Emergency Medical Services | 1 | 2012 | 209 | 0.020 |
Why?
|
| Matched-Pair Analysis | 1 | 2008 | 43 | 0.020 |
Why?
|
| Transcription Factors | 1 | 2016 | 1565 | 0.020 |
Why?
|
| Lacrimal Apparatus | 1 | 2008 | 11 | 0.020 |
Why?
|
| Histamine H1 Antagonists, Non-Sedating | 1 | 2008 | 13 | 0.020 |
Why?
|
| Multivariate Analysis | 1 | 2011 | 999 | 0.020 |
Why?
|
| Models, Biological | 1 | 2015 | 1749 | 0.020 |
Why?
|
| Reflex | 1 | 2008 | 79 | 0.020 |
Why?
|
| Bone Neoplasms | 2 | 1984 | 322 | 0.020 |
Why?
|
| Phthalazines | 1 | 2008 | 39 | 0.020 |
Why?
|
| Probability | 1 | 2008 | 355 | 0.020 |
Why?
|
| Eye Diseases | 1 | 2008 | 53 | 0.020 |
Why?
|
| Reference Values | 1 | 1989 | 674 | 0.020 |
Why?
|
| Radiography | 2 | 2008 | 813 | 0.020 |
Why?
|
| Heart Ventricles | 1 | 1992 | 760 | 0.020 |
Why?
|
| Siblings | 1 | 2007 | 111 | 0.020 |
Why?
|
| Choristoma | 1 | 2007 | 68 | 0.020 |
Why?
|
| Practice Guidelines as Topic | 1 | 2013 | 1036 | 0.020 |
Why?
|
| Base Sequence | 1 | 2010 | 2330 | 0.020 |
Why?
|
| Inducible T-Cell Co-Stimulator Protein | 1 | 2005 | 18 | 0.020 |
Why?
|
| 5' Untranslated Regions | 1 | 2005 | 49 | 0.020 |
Why?
|
| Homozygote | 1 | 2005 | 200 | 0.020 |
Why?
|
| Sarcoma, Ewing | 1 | 1984 | 42 | 0.020 |
Why?
|
| Leukocytes, Mononuclear | 1 | 2005 | 196 | 0.020 |
Why?
|
| Up-Regulation | 1 | 2005 | 712 | 0.010 |
Why?
|
| Binding Sites | 1 | 2005 | 1098 | 0.010 |
Why?
|
| Esophageal Neoplasms | 1 | 1985 | 321 | 0.010 |
Why?
|
| Alleles | 1 | 2005 | 1128 | 0.010 |
Why?
|
| Metoprolol | 2 | 1991 | 30 | 0.010 |
Why?
|
| Anisakis | 1 | 2000 | 1 | 0.010 |
Why?
|
| Antibodies, Helminth | 1 | 2000 | 11 | 0.010 |
Why?
|
| Cell Line, Tumor | 1 | 2005 | 2426 | 0.010 |
Why?
|
| Ultrasonography | 1 | 2000 | 695 | 0.010 |
Why?
|
| Electrodes, Implanted | 1 | 1995 | 171 | 0.010 |
Why?
|
| Chondrosarcoma | 1 | 1974 | 48 | 0.010 |
Why?
|
| Physical Conditioning, Animal | 1 | 1993 | 19 | 0.010 |
Why?
|
| Consciousness | 1 | 1993 | 26 | 0.010 |
Why?
|
| Specimen Handling | 1 | 1992 | 98 | 0.010 |
Why?
|
| Receptors, Adrenergic, beta | 1 | 1991 | 72 | 0.010 |
Why?
|
| Atropine | 1 | 1990 | 59 | 0.010 |
Why?
|
| Electric Stimulation | 1 | 1991 | 347 | 0.010 |
Why?
|
| Nephrectomy | 1 | 1990 | 294 | 0.000 |
Why?
|
| Vindesine | 1 | 1985 | 9 | 0.000 |
Why?
|
| Bleomycin | 1 | 1985 | 98 | 0.000 |
Why?
|
| Methotrexate | 1 | 1985 | 249 | 0.000 |
Why?
|
| Radiotherapy Dosage | 1 | 1985 | 468 | 0.000 |
Why?
|
| Lymphatic Metastasis | 1 | 1985 | 486 | 0.000 |
Why?
|
| Cisplatin | 1 | 1985 | 612 | 0.000 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 1985 | 1076 | 0.000 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 1985 | 2438 | 0.000 |
Why?
|
| Neoplasm Metastasis | 1 | 1974 | 1056 | 0.000 |
Why?
|